Working to Find a Cure for Charcot-Marie-Tooth: Keith Fargo, PhD


The chief scientific officer of the CMT Research Foundation discussed the foundation’s mission.

“People lose the ability to walk correctly, they begin to fall quite a bit. And then sometimes they lose the use of their hands as well. Braces can really help with keeping people able to do their activities of daily living and everyday tasks. But as of yet, there's really nothing that provides an effective treatment or a cure. And that's what the research foundation is here to provide.”

Charcot-Marie-Tooth disease (CMT) is a rare genetic disease for which no disease-modifying therapies exist today. CMT is a collection of hereditary peripheral neuropathies and those with the different types of CMT experience a gradual weakening of their sensory and motor muscles.

The CMT Research Foundation (CMTRF) was founded to support research that may lead to cures. The CMTRF funds a number of promising projects and research in CMT, many of which are taking cell or gene therapy approaches.

CGTLivespoke with Keith Fargo, PhD, chief scientific officer, CMTRF, to learn more about the CMTRF’s goals and mission. He discussed CMT and its disease burden on patients as well as the unmet needs in the disease.

Related Videos
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Frederick “Eric” Arnold, PhD
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
Jeffrey Chamberlain, PhD, on Exciting New Research at MDA 2024
Alan Beggs, PhD, on Challenges in Therapeutic Development for Rare Diseases
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
PJ Brooks, PhD
John DiPersio, MD, PhD, the director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine
Carlos Moraes, PhD, on Understanding Mitochondrial Mutations for Neurodegenerative Diseases
Aude Chapuis, MD, an associate professor in the Translational Science and Therapeutics Division at Fred Hutch Cancer Center
© 2024 MJH Life Sciences

All rights reserved.